Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - amoxicillin trihydrate 574mg equivalent to amoxycillin 500 mg;  ; potassium clavulanate 149mg equivalent to clavulanic acid 125 mg;   - film coated tablet - 500mg/125mg - active: amoxicillin trihydrate 574mg equivalent to amoxycillin 500 mg   potassium clavulanate 149mg equivalent to clavulanic acid 125 mg   excipient: croscarmellose sodium ethylcellulose hypromellose magnesium stearate microcrystalline cellulose povidone purified talc   purified water titanium dioxide triethyl citrate - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis and post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxycillin susceptible organisms are amenable to amoxycillin/clavulanic acid treatment due to its amoxycillin content. mixed infections caused by amoxycillin susceptible organisms in conjunction with amoxycillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxycillin/clavulanic acid.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - amoxicillin trihydrate 28.7 mg/ml equivalent to amoxycillin 25 mg/ml;  ; potassium clavulanate 8.6 mg/ml equivalent to clavulanic acid 6.25 mg/ml (plus 13% overage);  ;   - powder for oral suspension - 125mg,31.25mg/5ml - active: amoxicillin trihydrate 28.7 mg/ml equivalent to amoxycillin 25 mg/ml   potassium clavulanate 8.6 mg/ml equivalent to clavulanic acid 6.25 mg/ml (plus 13% overage)     excipient: aspartame citric acid guar gum hydrated silica lemon flavour 15020598 orange flavour 055301 ap0551 peach-apricot flavour 26f22 purified talc sodium citrate - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis and post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxycillin susceptible organisms are amenable to amoxycillin/clavulanic acid treatment due to its amoxycillin content. mixed infections caused by amoxycillin susceptible organisms in conjunction with amoxycillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxycillin/clavulanic acid.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - amoxicillin trihydrate 57.4 mg/ml equivalent to amoxycillin 50 mg/ml;  ; potassium clavulanate 17.2 mg/ml equivalent to clavulanic acid 12.5 mg/ml (pius 13% overage);  ;   - powder for oral suspension - 250mg, 62.5mg/5ml - active: amoxicillin trihydrate 57.4 mg/ml equivalent to amoxycillin 50 mg/ml   potassium clavulanate 17.2 mg/ml equivalent to clavulanic acid 12.5 mg/ml (pius 13% overage)     excipient: aspartame citric acid guar gum hydrated silica lemon flavour 15020598 orange flavour 055301 ap0551 peach-apricot flavour 26f22 purified talc sodium citrate - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis and post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxycillin susceptible organisms are amenable to amoxycillin/clavulanic acid treatment due to its amoxycillin content. mixed infections caused by amoxycillin susceptible organisms in conjunction with amoxycillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxycillin/clavulanic acid.

Malàisia - anglès - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sandoz products malaysia sdn. bhd. - amoxycillin trihydrate; potassium clavulanate -

República de Sud-àfrica - anglès - South African Health Products Regulatory Authority (SAHPRA)

sandoz south africa (pty) ltd - tablet - 562,5 mg 437,5 mg 62,5 mg - each tablet contains amoxicillin trihydrate equivalent to amoxicillin 562,5 mg amoxicillin sodium equivalent to amoxicillin 437,5 mg potassium clavulanate equivalent to clavulanic acid 62,5 mg

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - potassium clavulanate; amoxicillin trihydrate; amoxycillin trihydrate -

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - amoxicillin sodium 1.06 g equivalent to amoxicillin 1 g - as part of a 5:1 mix;  ; potassium clavulanate 238.3mg equivalent to clavulanic acid 200 mg - as part of a 5:1 mix - powder for injection - 1000/200mg - active: amoxicillin sodium 1.06 g equivalent to amoxicillin 1 g - as part of a 5:1 mix   potassium clavulanate 238.3mg equivalent to clavulanic acid 200 mg - as part of a 5:1 mix - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media; lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia; genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections; skin and soft tissue infections; bone and joint infections: e.g. osteomyelitis; other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxicillin susceptible organisms are amenable to amoxicillin/clavulanic acid treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organisms in conjunction with amoxicillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxicillin/clavulanic acid.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - amoxicillin sodium 530.1mg equivalent to amoxicillin 500 mg as part of a 5:1 mix;  ; potassium clavulanate 119.2mg equivalent to clavulanic acid 100 mg - as part of a 5:1 mix - powder for injection - 500/100mg - active: amoxicillin sodium 530.1mg equivalent to amoxicillin 500 mg as part of a 5:1 mix   potassium clavulanate 119.2mg equivalent to clavulanic acid 100 mg - as part of a 5:1 mix - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media; lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia; genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections; skin and soft tissue infections; bone and joint infections: e.g. osteomyelitis; other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxicillin susceptible organisms are amenable to amoxicillin/clavulanic acid treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organisms in conjunction with amoxicillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxicillin/clavulanic acid.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - amoxicillin sodium 2.12 g equivalent to amoxicillin 2 g - as part of a 10:1 mix;  ; potassium clavulanate 238.3mg equivalent to clavulanic acid 200 mg - as part of a 10:1 mix - powder for injection - active: amoxicillin sodium 2.12 g equivalent to amoxicillin 2 g - as part of a 10:1 mix   potassium clavulanate 238.3mg equivalent to clavulanic acid 200 mg - as part of a 10:1 mix - short term treatment of common bacterial infections such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media; lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho-pneumonia; genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections; skin and soft tissue infections; bone and joint infections: e.g. osteomyelitis; other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections. prophylaxis against infection which may be associated with major surgical procedures such as gastro-intestinal, pelvic, head and neck, cardiac, renal, joint replacement and biliary tract surgery. infections caused by amoxicillin susceptible organisms are amenable to amoxicillin/clavulanic acid treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organisms in conjunction with amoxicillin/clavulanic acid susceptible beta-lactamase-producing organisms may therefore be treated by amoxicillin/clavulanic acid.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxycillin trihydrate; potassium clavulanate -